

Investigation of a high-risk group that should be considered for cognitive function testing in diabetes treatment

Submission date 29/08/2019	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 07/09/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 10/12/2019	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

It is well known that the risk of cognitive disorder increases in diabetes patients, but there is no consensus regarding when patients should have a cognitive test or who should have the test. Because the cognitive test takes time, it is difficult to have a cognitive test for all diabetes patients. Searching the clinical parameters distinguished in diabetes patient saves time and effort. The aim of this study is to find out whether there is a high-risk group that should be considered for cognitive function testing in diabetes treatment.

Who can participate?

Patients with diabetes who were admitted to the Department of Diabetes and Metabolic Diseases at The University of Tokyo Hospital between 17/07/2016 and 31/03/2017.

What does the study involve?

Patient information is collected on the day of hospitalization and fasting blood samples are collected soon after obtaining informed consent.

What are the possible benefits and risks of participating?

The benefit is if the MMSE score has declined, the patient can have a medical examination of cognitive function, and can have treatment as quickly as possible. The risk is bleeding from blood collection.

Where is the study run from?

The University of Tokyo Hospital

When is the study starting and how long is it expected to run for?

The study was approved on 06/06/2016 and the recruitment was finished on 31/03/2017.

Who is funding the study?

University of Tokyo (Japan)

Who is the main contact?
Dr Yuka Kobayashi
kobayashiyu-int@h.u-tokyo.ac.jp

Contact information

Type(s)
Public

Contact name
Dr Yuka Kobayashi

Contact details
7-3-1 Hongo
Bunkyo-ku
Tokyo
Japan
1138655
+81 (0)3 5800 8815
kobayashiyu-int@h.u-tokyo.ac.jp

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
11171

Study information

Scientific Title
Which parameter is specific between normal cognitive function and declined cognitive function in diabetes patients?

Acronym
N/A

Study objectives
It is well known that the risk of cognitive disorder increases in diabetes patients. But, there is no consensus when patients should have a cognitive test or who should have the test. Because a cognitive test takes time, it is difficult to have a cognitive test for all diabetes patients. Searching the clinical parameters distinguished in diabetes patients saves time and effort.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 06/06/2016, Ethics Committee of the University of Tokyo (Office for Human Research Studies (OHRS), Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Faculty of Medicine Bldg.2 4F 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; Tel: +81 (0)3 5841 0818; Email: ethics@m.u-tokyo.ac.jp), No. 11171

Study design

Single-center observational cross-sectional study

Primary study design

Observational

Secondary study design

Cross sectional study

Study setting(s)

Hospital

Study type(s)

Screening

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Diabetes mellitus

Interventions

The researchers investigated the following parameters: sex, age, disease duration, body mass index (BMI), smoking, alcohol consumption, family history of diabetes mellitus, coronary artery disease, stroke, neuropathy, retinopathy, nephropathy, systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure, diabetic treatment, use of antihypertensive drugs, use of lipid-lowering drugs, HbA1c, glycoalbumin (GA), GA/HbA1c ratio, homeostasis model assessment-insulin resistance (HOMA-IR), fasting C-peptide immunoreactivity (CPR), 2-h-after-meal CPR, C-peptide Index (CPI), fasting plasma glucose (FPG), serum albumin (Alb), uric acid (UA), triglycerides (TG), calculated LDL cholesterol (c-LDL), blood urea nitrogen (BUN), creatinine (Cre), estimated glomerular filtration rate (eGFR), HNA% and Mini Mental State Examination (MMSE) score. Doctors and nurses answered a questionnaire which percent they think the patient has cognitive dysfunction before knowing the MMSE score. Neuropathy was diagnosed when the patient has at least one of the following findings: (1) coefficient of variation of R-R intervals (CVR-R) under 2%, (2) reduction in Achilles tendon reflex, (3) decreased lower limb vibration sensing, (4) and the presence of obvious sensory impairment. Retinopathy was diagnosed and classified into normal (-), simple diabetic retinopathy (SDR), pre-proliferative diabetic retinopathy (PPDR), or proliferative diabetic retinopathy (PDR), according to the Davis classification. Nephropathy stage was determined by urinary albumin excretion and eGFR, according to the Classification of Diabetic Nephropathy 2014 proposed by the Joint Committee on Diabetic Nephropathy in Japan. Patient background information was collected on the day of hospitalization and fasting blood samples were collected soon after obtaining informed consent.

Intervention Type

Other

Primary outcome measure

Cognitive dysfunction is measured using the Mini Mental State Examination (MMSE) score after getting consent.

Secondary outcome measures

Oxidative stress is measured using human non-mercaptalbumin (HNA%) from a morning blood test taken on the first day after getting consent.

Overall study start date

01/01/2012

Completion date

31/12/2018

Eligibility**Key inclusion criteria**

Inpatients diagnosed with diabetes mellitus, who were admitted to the Department of Diabetes and Metabolic Diseases at The University of Tokyo Hospital between 17/07/2016 and 31/03/2017

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

200

Total final enrolment

200

Key exclusion criteria

1. Pregnant
2. Lactating
3. Acute organ failure (e.g., pneumonia, acute myocardial infarction, acute cerebral infarction, diabetic ketoacidosis, and hyperosmolar hyperglycemic state)
4. Congenital cognitive disorders

Date of first enrolment

17/07/2016

Date of final enrolment

31/03/2017

Locations

Countries of recruitment

Japan

Study participating centre

Tokyo University Hospital

7-3-1 Hongo, Bunkyo-ku

Tokyo

Japan

1138655

Sponsor information

Organisation

University of Tokyo

Sponsor details

7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

Tokyo

Japan

113-8655

+81 (0)3 5800 8815

kobayashiyu-int@h.u-tokyo.ac.jp

Sponsor type

University/education

ROR

<https://ror.org/057zh3y96>

Funder(s)

Funder type

University/education

Funder Name

University of Tokyo

Alternative Name(s)

The University of Tokyo, , , , Utokyo

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

Japan

Funder Name

Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering

Alternative Name(s)

Nakatani Foundation

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Japan

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

30/06/2020

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Yuka Kobayashi (yukaodawara@aol.com or kobayashiyu-int@h.u-tokyo.ac.jp).

IPD sharing plan summary

Available on request